Acumen Pharmaceuticals (ABOS) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$2.14
+1.9% on the day
-4.9% over 12 months
52-week range $1.55 – $3.37
Share price and insider trades
ABOS closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$626K
Insiders buying0
Insiders selling9
Acumen Pharmaceuticals insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 9 sold $626K of ABOS stock on the open market.
Get emailed when insiders cluster-buy stocks like ABOS
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ABOS insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | $90K | 4 |
| Q1 2026 | — | 0 | $536K | 44 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.3×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Acumen Pharmaceuticals, Inc. insiders reported open-market purchases totaling $0, while 9 insiders reported sales totaling $626K. 44 of 48 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ABOS earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 12, 2026 | +12.3% | None | +3.2%S&P +0.9% | +14.5% |
| May 12, 2026 | +0.0% | None | -3.1%S&P +0.4% | -4.8% |
| Mar 26, 2026 | -21.7% | Sold $35K | -14.1%S&P -3.5% | +13.7% |
| Nov 12, 2025 | -10.5% | None | -8.1%S&P -1.6% | +18.2% |
| Aug 12, 2025 | -9.6% | None | -10.6%S&P +1.4% | +3.9% |
| May 13, 2025 | -2.8% | None | -6.7%S&P +0.8% | +9.2% |
| Mar 27, 2025 | -8.7% | None | +2.6%S&P -2.3% | -9.2% |
| Nov 12, 2024 | +11.0% | None | -21.4%S&P -0.3% | -19.8% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jun 17SEC | Derrell PorterDirector | Sell | 13,04035,500 held (−27%) | $2.33 | $30K | -8.2% | — |
| Jun 17SEC | Derrell PorterDirector | Sell | 12,80035,500 held (−27%) | $2.33 | $30K | -8.2% | — |
| Jun 17SEC | Derrell PorterDirector | Sell | 6,46048,300 held (−12%) | $2.35 | $15K | -8.9% | — |
| Jun 10SEC | Nathan B FountainDirector | Sell | 6,40048,150 held (−12%) | $2.23 | $14K | -4.0% | — |
| Mar 10SEC | Derek M MeisnerGeneral Counsel | Sell Plan | 2,090173,999 held (−1%) | $3.26 | $7K | -34.4% | — |
| Mar 3SEC | Derek M MeisnerGeneral Counsel | Sell Plan | 9,406173,999 held (−5%) | $3.01 | $28K | -28.9% | — |
| Jan 28SEC | Derek M MeisnerGeneral Counsel | Sell Plan | 15,085173,999 held (−8%) | $3.00 | $45K | -28.7% | — |
| Jan 28SEC | Derek M MeisnerGeneral Counsel | Sell Plan | 2,671173,999 held (−2%) | $3.00 | $8K | -28.7% | — |
| Jan 23SEC | Daniel Joseph OconnellCEO | Sell Plan | 9,346883,964 held (−1%) | $1.81 | $17K | +18.2% | — |
| Jan 23SEC | Derek M MeisnerGeneral Counsel | Sell Plan | 5,633173,999 held (−3%) | $1.90 | $11K | +12.6% | — |
| Jan 23SEC | Daniel Joseph OconnellCEO | Sell Plan | 2,689881,275 held (−0%) | $1.88 | $5K | +13.8% | — |
| Jan 23SEC | Matt ZugaCFO | Sell Plan | 2,473306,611 held (−1%) | $1.81 | $4K | +18.2% | — |
| Jan 23SEC | Eric SiemersChief Medical Officer | Sell Plan | 2,331256,266 held (−1%) | $1.80 | $4K | +18.9% | — |
| Jan 23SEC | Russell BartonCOO | Sell Plan | 2,315205,554 held (−1%) | $1.81 | $4K | +18.2% | — |
| Jan 23SEC | Derek M MeisnerGeneral Counsel | Sell Plan | 2,247180,686 held (−1%) | $1.81 | $4K | +18.2% | — |
| Jan 23SEC | Matt ZugaCFO | Sell Plan | 1,687304,924 held (−1%) | $1.86 | $3K | +15.1% | — |
| Jan 23SEC | Derek M MeisnerGeneral Counsel | Sell Plan | 1,054179,632 held (−1%) | $1.84 | $2K | +16.3% | — |
| Jan 23SEC | Eric SiemersChief Medical Officer | Sell Plan | 895255,371 held (−0%) | $1.82 | $2K | +17.6% | — |
| Jan 23SEC | Russell BartonCOO | Sell Plan | 462205,092 held (−0%) | $1.84 | $850 | +16.3% | — |
| Jan 12SEC | Derek M MeisnerGeneral Counsel | Sell Plan | 30,09297,548 held (−24%) | $1.82 | $55K | +17.6% | — |
| Jan 12SEC | Daniel Joseph OconnellCEO | Sell Plan | 12,941598,898 held (−2%) | $1.76 | $23K | +21.6% | — |
| Jan 12SEC | Daniel Joseph OconnellCEO | Sell Plan | 8,143611,839 held (−1%) | $1.82 | $15K | +17.6% | — |
| Jan 12SEC | Derek M MeisnerGeneral Counsel | Sell Plan | 8,54883,800 held (−9%) | $1.71 | $15K | +25.1% | — |
| Jan 12SEC | Matt ZugaCFO | Sell Plan | 6,888209,951 held (−3%) | $1.82 | $13K | +17.6% | — |
| Jan 12SEC | Derek M MeisnerGeneral Counsel | Sell Plan | 6,819127,640 held (−5%) | $1.82 | $12K | +17.6% | — |
| Jan 12SEC | Daniel Joseph OconnellCEO | Sell Plan | 5,388593,510 held (−1%) | $1.73 | $9K | +23.7% | — |
| Jan 12SEC | Derek M MeisnerGeneral Counsel | Sell Plan | 5,20092,348 held (−5%) | $1.76 | $9K | +21.6% | — |
| Jan 12SEC | Russell BartonCOO | Sell Plan | 3,530123,269 held (−3%) | $1.86 | $7K | +15.1% | — |
| Jan 9SEC | James J. DohertyPresident | Sell Plan | 6,46754,033 held (−11%) | $1.82 | $12K | +17.6% | — |
| Jan 9SEC | James J. DohertyPresident | Sell Plan | 1,70060,500 held (−3%) | $1.99 | $3K | +7.5% | — |
| Jan 9SEC | Amy SchacterleChief Regulatory Officer | Sell Plan | 1,0977,703 held (−12%) | $1.98 | $2K | +8.1% | — |
| Jan 7SEC | Daniel Joseph OconnellCEO | Sell Plan | 37,755619,982 held (−6%) | $1.99 | $75K | +7.5% | — |
| Jan 7SEC | Derek M MeisnerGeneral Counsel | Sell Plan | 10,070134,459 held (−7%) | $1.99 | $20K | +7.5% | — |
| Jan 7SEC | Derek M MeisnerGeneral Counsel | Sell Plan | 7,097150,030 held (−5%) | $1.97 | $14K | +8.6% | — |
| Jan 7SEC | Eric SiemersChief Medical Officer | Sell Plan | 6,834159,464 held (−4%) | $1.97 | $13K | +8.6% | — |
| Jan 7SEC | Daniel Joseph OconnellCEO | Sell Plan | 5,102657,737 held (−1%) | $1.97 | $10K | +8.6% | — |
| Jan 7SEC | Matt ZugaCFO | Sell Plan | 5,100222,644 held (−2%) | $1.97 | $10K | +8.6% | — |
| Jan 7SEC | Daniel Joseph OconnellCEO | Sell Plan | 4,649662,839 held (−1%) | $1.97 | $9K | +8.6% | — |
| Jan 7SEC | Matt ZugaCFO | Sell Plan | 4,105218,539 held (−2%) | $2.00 | $8K | +7.0% | — |
| Jan 7SEC | Russell BartonCOO | Sell Plan | 4,000132,117 held (−3%) | $1.96 | $8K | +9.2% | — |
| Jan 7SEC | Eric SiemersChief Medical Officer | Sell Plan | 4,000166,298 held (−2%) | $1.96 | $8K | +9.2% | — |
| Jan 7SEC | Derek M MeisnerGeneral Counsel | Sell Plan | 4,000157,127 held (−2%) | $1.96 | $8K | +9.2% | — |
| Jan 7SEC | Matt ZugaCFO | Sell Plan | 4,000227,744 held (−2%) | $1.96 | $8K | +9.2% | — |
| Jan 7SEC | Derek M MeisnerGeneral Counsel | Sell Plan | 3,801146,229 held (−3%) | $1.97 | $7K | +8.6% | — |
| Jan 7SEC | Russell BartonCOO | Sell Plan | 3,618128,499 held (−3%) | $1.97 | $7K | +8.6% | — |
| Jan 7SEC | Russell BartonCOO | Sell Plan | 1,700126,799 held (−1%) | $1.99 | $3K | +7.5% | — |
| Jan 7SEC | Derek M MeisnerGeneral Counsel | Sell Plan | 1,700144,529 held (−1%) | $1.99 | $3K | +7.5% | — |
| Jan 7SEC | Matt ZugaCFO | Sell Plan | 1,700216,839 held (−1%) | $1.99 | $3K | +7.5% | — |
Insiders at Acumen Pharmaceuticals, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Derek M MeisnerGeneral Counsel | — | $249K | Mar 10, 2026 | — |
| Daniel Joseph OconnellCEO | — | $163K | Jan 23, 2026 | — |
| Derrell PorterDirector | — | $75K | Jun 17, 2026 | — |
| Matt ZugaCFO | — | $50K | Jan 23, 2026 | — |
| Russell BartonCOO | — | $30K | Jan 23, 2026 | — |
| Eric SiemersChief Medical Officer | — | $27K | Jan 23, 2026 | — |
| James J. DohertyPresident | — | $15K | Jan 9, 2026 | — |
| Nathan B FountainDirector | — | $14K | Jun 10, 2026 | — |
| Amy SchacterleChief Regulatory Officer | — | $2K | Jan 9, 2026 | — |
ABOS stock: common questions
Are Acumen Pharmaceuticals, Inc. insiders buying ABOS stock?
In the past 12 months, 0 insiders reported open-market purchases of ABOS worth $0.
Are Acumen Pharmaceuticals, Inc. insiders selling ABOS stock?
9 insiders reported sales worth $626K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ABOS's 52-week range?
Over the past year ABOS has traded between $1.55 and $3.37. It last closed at $2.14 on Oct 9, 2026.